Drug makers reportedly to pledge they won't cut corners on coronavirus vaccine

Several American drug companies are trying to allay the public's fears about the mad dash for a coronavirus vaccine, The Wall Street Journal reports.
In a draft of a joint statement reviewed by the Journal, multiple companies developing and testing COVID-19 vaccines — including Pfizer, Johnson & Johnson, and Moderna — pledged not to seek government approval for their products until they have been proven safe and effective. The statement is still being finalized, but could reportedly be made public as soon as next week.
The Journal notes the pledge is "an unusual joint move among rivals," which comes amid concerns that the companies and the U.S. government may be rushing to approve a vaccine. President Trump, for instance, has (as recently as Friday night) said a vaccine is right around the corner, perhaps even by October. In turn, some of his critics have accused the White House of trying to push the Food and Drug Administration to sign off on a vaccine before the November election even if it hasn't undergone the usual scrutiny. But if the manufacturers stick to their pledge, those allegations could be irrelevant, whether they're valid or not.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"We believe this pledge will help ensure public confidence in the COVID-19 vaccines that may ultimately be approved and adherence to the rigorous scientific and regulatory process by which they are evaluated," the draft statement reportedly says. Read more at The Wall Street Jounral.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Rep. Sylvester Turner dies, weeks after joining House
Speed Read The former Houston mayor and longtime state legislator left behind a final message for Trump: 'Don't mess with Medicaid'
By Peter Weber, The Week US Published
-
Trump pauses Ukraine intelligence sharing
Speed Read The decision is intended to pressure Ukrainian President Volodymyr Zelenskyy into peace negotiations with Vladimir Putin
By Peter Weber, The Week US Published
-
Supreme Court rules against Trump on aid freeze
Speed Read The court rejected the president's request to freeze nearly $2 billion in payments for foreign humanitarian work
By Rafi Schwartz, The Week US Published
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US Published
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published